Stryker (NYSE:SYK) Sets New 12-Month Low - Should You Sell?

Key Points

• Stryker shares fell 8.9% to a new 52-week low of $275.10, well below their 50-day and 200-day moving averages near $328.
• Despite the selloff, analysts maintain a “Moderate Buy” consensus with an average price target of $386.28; recent firms lowered targets but generally retained overweight or outperform ratings.
• Stryker recently exceeded quarterly earnings and revenue expectations, with revenue up 9.4% year over year, while declaring a quarterly dividend of $0.88 per share. However, insiders sold more than 351,000 shares worth about $118.2 million during the last quarter.

Stryker Corporation (NYSE:SYK - Get Free Report)'s share price reached a new 52-week low during trading on Wednesday . The company traded as low as $275.10 and last traded at $276.1560, with a volume of 6316453 shares changing hands. The stock had previously closed at $303.13.

Wall Street Analyst Weigh In

SYK has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Stryker in a research note on Friday, July 31st. Piper Sandler dropped their target price on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a report on Friday, July 31st. JPMorgan Chase & Co. decreased their price target on Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a research note on Friday, July 31st. BMO Capital Markets started coverage on Stryker in a report on Wednesday, July 8th. They issued an "outperform" rating and a $369.00 price target on the stock. Finally, Leerink Partners reduced their price objective on Stryker from $410.00 to $407.00 and set an "outperform" rating for the company in a report on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Stryker has an average rating of "Moderate Buy" and a consensus target price of $386.28.

Stryker Stock Down 8.9%

The firm's fifty day simple moving average is $327.52 and its 200-day simple moving average is $328.30. The company has a market cap of $105.93 billion, a PE ratio of 28.62, a P/E/G ratio of 1.90 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company's quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts expect that Stryker Corporation will post 15.03 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.3%. Stryker's dividend payout ratio (DPR) is presently 36.48%.

Insider Buying and Selling

In related news, insider Debra King sold 826 shares of the business's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares of the company's stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the company's stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by corporate insiders.

Institutional Trading of Stryker

A number of hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System boosted its holdings in shares of Stryker by 30,523.4% during the second quarter. California State Teachers Retirement System now owns 163,395,348 shares of the medical technology company's stock worth $51,443,391,000 after purchasing an additional 162,861,784 shares during the last quarter. Norges Bank acquired a new position in Stryker in the fourth quarter valued at $1,822,272,000. Bank of America Corp DE purchased a new position in Stryker during the second quarter worth about $1,404,284,000. Auto Owners Insurance Co boosted its stake in Stryker by 35,047.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company's stock worth $1,024,444,000 after buying an additional 2,906,448 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Stryker during the 2nd quarter valued at about $707,212,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker's principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.